KLOX Technologies reports on final results from its clinical study on LumiHeal(TM) for the treatment of chronic wounds
LAVAL, Quebec, May 03, 2017 (GLOBE NEWSWIRE) -- Today, the final results on KLOX Technologies' (Klox) EUREKA study, which evaluated LumiHeal in the treatment of hard-to-heal, non-responsive, chronic wounds, were reported at the European Wound Management Association, in Amsterdam.
LumiHeal is a CE marked, first-in-class, proprietary, non-thermal and non-invasive treatment solution that utilizes hyper pulsed fluorescence light (HPFL) to treat acute and chronic wounds.
"LumiHeal has shown that it is a viable and effective treatment solution for patients with debilitating hard-to-heal, chronic wounds," stated Dr. Marco Romanelli, MD, PhD, Associate Professor of Dermatology at the School of Medicine, University of Pisa, and Chief of the Wound Healing Research Unit, and President Elect of the World Union of Wound Healing Societies. "LumiHeal represents a new option in the way practitioners can manage and treat hard-to-heal chronic wounds."
"We are very pleased that the data released today confirmed the interim analysis reported in September 2016 on 33 patients," said Dr. Michel Cimon, MD, Senior Vice President, Chief Medical and Scientific Officer at Klox. "It's an important day for LumiHeal and for FB Advanced Wound Care, our wound care franchise."
Clinical final results from EUREKA study on LumiHeal(TM) and chronic wounds management
Professor Marco Romanelli reported the final study results on the evaluation of real-life use of LumiHeal in Chronic Wounds Management (Venus Leg Ulcers, Diabetic Foot Ulcers, and Pressure Ulcers). The results reported were on 99 patients who completed treatment in the EUREKA study.
Investigators' final analysis supports the strong efficacy profile of LumiHeal in promoting wound closure along with wound bed preparation in hard-to-heal chronic wounds. These results indicate LumiHeal's ability, in a majority of cases, to transition hard-to-heal, non-responsive, chronic wounds into an acute wound setting.
Investigators found the treatment to be safe, easy to administer and very well tolerated by the subjects' population. Compliance to the study visits was excellent.
The excellent tolerability and compliance profiles is reinforced by the positive action on pain reduction observed during this study, especially in the VLU population.
Final results show:
Out of the 99 patients reported, 71% of them had a prognosis factor of poor healing at study entry;
The average treatment duration for all types of wounds was 80.5 days;
47 of these hard-to heal, chronic wounds, closed completely during the study period VLUs (26), DFUs (16), PU (5);
96% of wounds that closed completely, remained closed throughout the follow up period;
69.2% of VLUs and 68.8% of DFUs were ready for skin graft according to clinician's opinion;
The table below summarizes the top line data:
at last Study
The final results of the EUREKA study show, that taken together with efficacy, treatment ease of use, safety, and a positive impact on pain reduction, LumiHeal has the ability to become a leading option for the treatment and management of hard-to-heal, chronic wounds.
LumiHeal is a CE marked, first-in-class, proprietary, non-thermal and non-invasive treatment solution that generates hyper pulsed fluorescence light to treat acute and chronic wounds. It is used in conjunction with a multi-LED light. LumiHeal is a topical gel comprising of light absorbing molecules, which is applied to a wounded area. The HPFL generated have the capacity to penetrate various depths of the skin (epidermis, dermis, hypodermis). Treatment duration lasts only a number of minutes, while maintaining a safe and well tolerated product profile.
About KLOX Technologies
Klox is a specialty pharmaceutical company focused on developing and commercializing products based on its proprietary Fluorescence Biomodulation technology platform, previously known as BioPhotonics, to address skin and soft tissue disorders. Klox is advancing its programs as part of its multiple franchises focusing on indications across Dermatology, Wound Care, and Oral Health. For more information and to consult the abstracts, please visit www.kloxtechnologies.com.
Forward Looking Statements
Certain statements contained in this newswire, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward looking statements include those regarding cosmetics and medical devices and medical applications and clinical trials and the status and related results thereto, as well those regarding continuing and further development and commercialization efforts. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Klox Technologies Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the medical, cosmetics and/or consumer goods industries, changes in the regulatory environment in the jurisdictions in which Klox Technologies Inc. does business, financial and commercial markets volatility, fluctuations in costs, and changes to the competitive environment, as well as other risks. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing and further development efforts, specific risks which could cause actual results to differ materially from Klox Technologies Inc.'s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our products, final and quality controlled verification of data and the related analyses, and the expense and uncertainty of obtaining regulatory approval.
For more information:
Jade Lavallée Labossière
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: KLOX Technologies Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Hattrick för LeoVegas vid EGR Nordics Awards 201822.1.2018 08:00 | Pressmeddelande
Vid EGR Nordics Awards lyfts de mest framgångsrika och innovativa spelbolagen fram. I hård konkurrens vann LeoVegas tre utmärkelser, "Nordics Operator of the Year", "Casino Operator of the Year" och "Sports Betting Operator of the Year" "Vi är väldigt glada över att ha vunnit Casino Operator- och Sports Betting Operator of the Year eftersom det är dessa två spelkategorier som definierar, och är vår produkt. Att dessutom bli utsedd till Nordics Operator of the Year är helt fantastiskt! Att få dessa utmärkelser är ett kvitto på att vi är ett extremt duktigt team på LeoVegas som ständigt levererar. Det visar också att vi är det ledande GameTech bolaget som verkligen leder vägen inom Norden", säger Gustaf Hagman, Group CEO. Nordics Operator of the Year LeoVegas vann utmärkelsen Nordics Operator of the Year för att LeoVegas har under det senaste året varit en drivkraft för innovation inom alla delar av bolagets verksamhet och tydligt lyckats särskilja sig från konkurrenterna genom en mix av
Hat-trick for LeoVegas at EGR Nordics Awards 201822.1.2018 08:00 | Pressmeddelande
The most successful and innovative gaming companies are noticed at the EGR Nordic Awards. In fierce competition, LeoVegas won three awards, "Nordics Operator of the Year", "Casino Operator of the Year" and "Sports Betting Operator of the Year". "We are extremely pleased to have won the Casino Operator and the Sports Betting Operator awards as these are the two main categories that define our product. Being declared as the Nordics Operator of the Year is really outstanding! To receive these awards is a receipt that we are an extremely talented team at LeoVegas that is constantly delivering. It also shows that we are the GameTech company that is leading the way within the Nordic region," says Gustaf Hagman, Group CEO. Nordics Operator of the Year LeoVegas won the award for the Nordics Operator of the Year because LeoVegas has been the driving force for innovation in all parts of the company and clearly distinguished from its competitors through a mix of high growth, innovation and strong
Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February22.1.2018 08:00 | Pressmeddelande
Press Release 22 January 2018 Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, today announced that Immunicum leadership will present the Company and attend several upcoming industry and scientific conferences in January and February. ASCO/SITC - Clinical Immuno-Oncology Symposium Date: January 25 - 27, 2018 Venue: San Francisco Marriott Marquis, San Francisco, California Aktiedagen Lund Date: January 30, 2018 Presentation: Tuesday, January 30, 10:15 am Central European Time Venue: Medicon Village, Hörsalen Scheelevägen 2, Lund, Sweden Please register to attend at https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-30-januari Cholangiocarcinoma Foundation Annual Conference Date: January 31 - February 2, 2018 Presentation: Poster Session - Thursday, February 1, 7:00 - 9:00 pm Mountai
Immunicum AB (publ) meddelar kommande presentationer och deltagande i konferenser under januari och februari22.1.2018 08:00 | Pressmeddelande
Pressmeddelande 22 januari 2018 Immunicum AB (publ) meddelar kommande presentationer och deltagande i konferenser under januari och februari Immunicum AB (IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelar idag att Immunicums ledning kommer att presentera bolaget och delta under flera kommande branschkonferenser och forskningskonferenser under januari och februari. ASCO/SITC - Clinical Immuno-Oncology Symposium Datum: 25-27 januari 2018 Plats: San Francisco Marriott Marquis, San Francisco, Kalifornien, USA Aktiedagen Lund Datum: 30 januari 2018 Presentation: tisdag den 30 januari, 10:15 CET Plats: Medicon Village, Hörsalen Scheelevägen 2, Lund För att delta, registrera dig här https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-30-januari Cholangiocarcinoma Foundation Annual Conference Datum: 31 januari-2 februari 2018 Presentation: Poster Session: torsdag den 1 februari, kl. 19:00-21:00 Mountain Standard
SD-WAN Market Leader Aryaka Names Claudio Perugini Senior Vice President of Global Channels22.1.2018 06:00 | Pressmeddelande
SAN MATEO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, announced today that networking industry veteran Claudio Perugini has joined the company's leadership team as Senior Vice President of Global Channels. In his new role, Perugini will lead and further scale Aryaka's global partner program as the company continues to grow rapidly and expand its market footprint in 2018. "Aryaka's channel partners have played an essential role in establishing the company as the market leader in the global SD-WAN space," said Perugini. "Our technology is a game-changer for the channel community as we offer global enterprises a next-generation alternative to legacy network technologies. As the Senior Vice President of Global Channels, my key focus areas will be recruitment, further scaling the channel organization, enhancing the structure of the Aryaka Global Partner Program, and improving partner enablement." Perugini has more than 30 years of channel and sale
Ant Financial Hosts Technology Conference in Silicon Valley20.1.2018 06:39 | Pressmeddelande
Conference featured global fintech leaders and showcased Ant Financial's capabilities across blockchain, AI, security, IoT and computing SANTA CLARA, Calif., Jan. 20, 2018 (GLOBE NEWSWIRE) -- Ant Financial today hosted the Ant Technology Exploration Conference (ATEC) in Silicon Valley, bringing together global partners and technology leaders to explore new innovations and technologies that further Ant Financial's mission of bringing the world equal opportunities. This was the first ATEC held outside of China, following the inaugural ATEC held in Hangzhou in October 2017. The conference featured a diverse range of speakers from academia and industry to better explore the future of fintech, including Turing Award winner and MIT Professor Silvio Micali; Partner and Director of blockchain-based global payment platform Ripple, Emi Yoshikawa; founder of prediction market Bodhi, Xiahong Lin; and Director of JPMorgan Chase's digital channels, Umar Farooq, among others. Ant Financial's Vice Pre
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum